PITTSBURGH, Jan. 7, 2025 /PRNewswire/ — Avista Therapeutics, a pre-clinical-stage biotechnology company developing innovative gene therapies for rare ophthalmic conditions, today announced the appointment of Steven Altschuler, MD, as the Chairman of the Board of Directors. Dr. Altschuler…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.